Arctic Bioscience - Mandatory notification of trade

Ronja Capital AS, a legal person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has today transferred 3,087,999 shares in Arctic Bioscience to Ronja Capital Investment AS at an average price of NOK 13,50 per share. Both companies are controlled by Roger Halsebakk and closely related to board member Tore Tønseth in Arctic Bioscience AS. After the transaction Ronja Capital AS holds 0 shares and Ronja Capital Investment AS holds 3,087,999 shares in Arctic Bioscience AS, corresponding to an ownership of 12.17 % of the issued and outstanding share capital in Arctic Bioscience AS. The transaction is related to internal restructuring of Ronja Capital AS. Member of the Board of Directors, Tore A. Tønseth, is Investment Director at Ronja Capital AS. Please refer to the attached notification of trading for further details. This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19 and the Norwegian Securities Trading Act § 5-12. For more information, please contact: Jone R. Slinning CFO Phone: +47 948 75 469 E-mail: jone@arctic-bioscience.com About Arctic Bioscience Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds. The company is developing HRO350 - a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile. Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand. Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.